HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

bromohydrin pyrophosphate

stimulates human gammadelta T cells; structure in first osurce

Networked: 8 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Sicard, Hélène: 2 articles (10/2010 - 05/2009)
2.	Romagne, François: 2 articles (07/2010 - 04/2008)
3.	Scaglione, Virginie: 2 articles (07/2010 - 05/2009)
4.	Escudier, Bernard: 2 articles (04/2008 - 12/2005)
5.	Viey, Emilie: 2 articles (04/2008 - 12/2005)
6.	Durbaka, Prasad V R: 1 article (01/2014)
7.	Latha, T Sree: 1 article (01/2014)
8.	Lomada, Dakshayani: 1 article (01/2014)
9.	Pallu, Reddanna: 1 article (01/2014)
10.	Rachamallu, Aparna: 1 article (01/2014)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2010 - "Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors." 07/01/2010 - "Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells." 04/01/2008 - "We previously showed that Vdelta2 T cells infiltrate renal tumors and can be expanded as potent cytotoxic effectors from peripheral blood mononuclear cells of most renal cell carcinoma (RCC) patients, using a structural analog of nonconventional T-cell receptor gamma9delta2 ligand, bromohydrin pyrophosphate, and interleukin-2 (IL-2). " 01/01/2014 - "Enhancing the human Vγ9Vδ2 T cells functions by administration of aminobisphosphonates like zoledronate, pamidronate, and bromohydrin pyrophosphate along with cytokines and monoclonal antibodies shows a hopeful approach for treatment of tumors and infections. "
2.	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/15/2012 - "The first proof of concept of this new immunotherapy approach was demonstrated with the synthetic phosphoantigen named bromohydrin pyrophosphate (BrHPP, IPH 1101) which was administrated in racemic form to about 200 patients in six clinical trials with good safety and promising early signals of efficacy in type C viral hepatitis and follicular non-Hodgkin's lymphoma. "
3.	Hepatitis 09/15/2012 - "The first proof of concept of this new immunotherapy approach was demonstrated with the synthetic phosphoantigen named bromohydrin pyrophosphate (BrHPP, IPH 1101) which was administrated in racemic form to about 200 patients in six clinical trials with good safety and promising early signals of efficacy in type C viral hepatitis and follicular non-Hodgkin's lymphoma. "
4.	Renal Cell Carcinoma (Grawitz Tumor) 12/01/2005 - "Preclinical results obtained on specific in vitro amplification of Vgamma9Vdelta2 T-cells by bromohydrin pyrophosphate in renal cell carcinoma patients are presented in this review, while Phase I clinical trials are currently running. " 04/01/2008 - "We previously showed that Vdelta2 T cells infiltrate renal tumors and can be expanded as potent cytotoxic effectors from peripheral blood mononuclear cells of most renal cell carcinoma (RCC) patients, using a structural analog of nonconventional T-cell receptor gamma9delta2 ligand, bromohydrin pyrophosphate, and interleukin-2 (IL-2). "
5.	Neuroblastoma 07/01/2010 - "Using a synthetic phosphoantigen (Bromohydrin Pyrophosphate, BrHPP), we amplified Vgamma9delta2 T cells in vitro from neuroblastoma patients. " 07/01/2010 - "Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells."

Related Drugs and Biologics

1.	Interleukin-2 (IL2)
2.	Monoclonal Antibodies
3.	Rituximab (Mabthera)
4.	Cytokines
5.	T-Cell Antigen Receptors (T-Cell Receptor)
6.	Ligands
7.	Pamidronate (Aredia)
8.	Zoledronic Acid (Zometa)
9.	ofatumumab

Related Therapies and Procedures

1.	Immunotherapy